TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03261882

Intervention type: OTHER
Intervention: Nativity
Description: Mexican-American children were subdivided into two groups based on their country of birth. Mexican-American children who were not born in the U.S. were considered foreign-born and those born in the U.S. were U.S.-born.

Intervention type: OTHER
Intervention: Nativity
Description: Mexican-American children were subdivided into two groups based on their country of birth. Mexican-American children who were not born in the U.S. were considered foreign-born and those born in the U.S. were U.S.-born.
Study: NCT03720574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg BID
Description: Lorcaserin 10 mg tablet each morning and evening for a duration of 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo BID
Description: Matching Placebo tablet each morning and evening for a duration of 48 weeks
Study: NCT00998972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 600 mg intravenous before and 2 hours after cerebral arteriography
Study: NCT03421366

Intervention type: DRUG
Intervention: Posaconazole
Description: A triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients
Study: NCT01194973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
Study: NCT04471402

Intervention type: DRUG
Intervention: Precedex
Description: Intranasal Precedex 3mcg/kg
Study: NCT02027870

Intervention type: DEVICE
Intervention: EXCEL-II biodegradable polymer sirolimus-eluting stent
Description: EXCEL-II biodegradable polymer sirolimus-eluting stent implantation
Study: NCT03658187

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IP
Description: Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: IP
Description: Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.
Study: NCT01470196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg IV on Days 1, 2, 8, 9, of 21 day cycle for cycles 1-6 20 mg IV on Days 1, 2 of 21 day cycles q 2 months for cycles 1-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 20 mg/m2 IV on Days 1, 2, 8, 9 of 21 day cycles for Cycle 1 36 mg/m2 IV on Days 1, 2, 8, 9 of 21 day cycles for Cycles 2-6 36 mg/m2 IV on Days 1, 2 of 21 day cycles q 2 months for Cycles 1-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV on Days 2, 9 of 21 day cycles for Cycles 1-6 375 mg/m2 IV on Day 2 of 21 day cycles q 2 months for Cycles 1-8
Study: NCT03469817

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI
Description: Patients who are part of Arm 2 will undergo an MRI at their 1 year post-operative visit.
Study: NCT04702763

Intervention type: OTHER
Intervention: Eye-Tracker®T2 + e-VOG
Description: * 1st step: eyes movements assessed with standard video-oculography device~* 2° step: eyes movements assessed with e-VOG digital application~* Patient study duration is about 30 minutes, the day the patient performs their standard video-oculography examination in routine care

Intervention type: OTHER
Intervention: e-VOG + Eye-Tracker®T2
Description: * 1st step: eyes movements assessed with e-VOG digital application~* 2° step: eyes movements assessed with standard video-oculography device~* Patient study duration is about 30 minutes, the day the patient performs their standard video-oculography examination in routine care
Study: NCT03560687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucrosomial Iron
Description: CardioSideral 2 caps per day
Study: NCT04079491

Intervention type: OTHER
Intervention: questionnaire survey
Description: A web-based questionnaire will be send by the trade union for dental hygienists
Study: NCT03694808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluad Vaccine
Description: single adjuvanted dose (AD) intramuscular injection
Study: NCT04620161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pradigastat Tablets 20mg
Description: 20mg, once daily, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pradigastat Tablets 40mg
Description: 40mg, once daily, oral administration
Study: NCT00869323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.3 mg/m\^2 intravenous bolus days 1, 8, 15 and 22
Study: NCT01573130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise program
Description: An individualized physical exercise program, administered per internet. Some therapist-support will also be included.
Study: NCT04778917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-Molecular-Weight Heparins Calcium Injection
Description: We use different dose of low-molecular-weight heparins calcium injection to different interventions
Study: NCT04620161

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pradigastat Tablets 20mg matching Placebo
Description: once daily, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pradigastat Tablets 20mg matching Placebo
Description: once daily, oral administration
Study: NCT04778917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-Molecular-Weight Heparins Calcium Injection
Description: We use different dose of low-molecular-weight heparins calcium injection to different interventions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low-Molecular-Weight Heparins Calcium Injection
Description: We use different dose of low-molecular-weight heparins calcium injection to different interventions
Study: NCT02841150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMBRUVICA (Treatment A)
Description: IMBRUVICA (reference treatment), 4\*140 milligram (mg), capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMBRUVICA (Treatment A)
Description: IMBRUVICA (reference treatment), 4\*140 milligram (mg), capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment B)
Description: Ibrutinib (test treatment), 1\*560 mg, tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment B)
Description: Ibrutinib (test treatment), 1\*560 mg, tablet.
Study: NCT00364013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab 6 mg/kg over on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Description: The FOLFOX regimen consisted of oxaliplatin 85 mg/m\^2 intravenous (IV) infusion on Day 1, leucovorin, 200 mg/m\^2 (racemate) on Days 1 and 2 and 5-fluorouracil 400 mg/m\^2 IV bolus followed by 600 mg/m\^2 IV infusion over 22 hours on Days 1 and 2. Each cycle was 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: The FOLFOX regimen consisted of oxaliplatin 85 mg/m\^2 intravenous (IV) infusion on Day 1, leucovorin, 200 mg/m\^2 (racemate) on Days 1 and 2 and 5-fluorouracil 400 mg/m\^2 IV bolus followed by 600 mg/m\^2 IV infusion over 22 hours on Days 1 and 2. Each cycle was 14 days.
Study: NCT04122937

Intervention type: PROCEDURE
Intervention: Cytoreductive surgery
Description: Partial removal of peritoneal tissue involved by neoplastic invasion

Intervention type: PROCEDURE
Intervention: Cytoreductive surgery
Description: Partial removal of peritoneal tissue involved by neoplastic invasion
Study: NCT02576613

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MPP-S
Description: \> 30 weekly sessions of modified psychodynamic psychotherapy in addition to standard treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAU
Description: standard medical treatment without structured psychotherapeutic intervention
Study: NCT01591239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-Based Intervention
Description: Parents will be trained through a 3 1/2-hour series on providing a 3-session drug and alcohol intervention program to their adolescent. The parent-led intervention will require parents to meet with their adolescent and work together to help strengthen family cohesiveness, enhance communication, and promote healthy life choices.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Group
Description: Printed fact sheets will be delivered to parents in a single two-hour session. These fact sheets will provide general drug-related information from the public domain (e.g., substance use trends and well-known dangers of substance involvement), and focus on communication approaches and talking points when discussing substance use with their adolescent (e.g., why adolescents use; how the media may influence attitudes about substances).
Study: NCT00187941

Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate Mofetil
Description: Targeted MPA exposure to 30-60 mg/L/h during the first month post-transplant.
Study: NCT02889237

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: Immediate administration of daily calcium supplementation for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium + low dose vitamin D
Description: Immediate administration of daily calcium and low dose vitamin D (1 sachet CaD 1000/880) supplementation for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium + high dose vitamin D
Description: Immediate administration of daily calcium and high dose vitamin D (2 sachets CaD 500/880) supplementation for 12 weeks
Study: NCT01895218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside 1000
Description: A single dose of 1200 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9 % sodium chloride and given over approximately 15 min.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical Care
Description: Standard medical Care is most often to recommend women with PPH to continue oral iron supplementation as recommended during pregnancy or to advise the subject to take 100 mg oral iron 1-2 times a day
Study: NCT01069523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine Extended Release
Description: Guanfacine is an alpha-2A agonist which is given one a day. the dose range is 1-4 mg. It is a tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Table that match the 1 mg Guanfacine Extended Release Tablet. They are dosed once a day.
Study: NCT03840083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep
Description: Participants will sleep (either a mid-day nap or normal overnight sleep)
Study: NCT01449201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00299804
Description: 45 mg P.O. Daily (28-day treatment as one treatment cycle)
Study: NCT03217773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESD
Description: Refer to arm description

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAMIS
Description: Refer to arm description
Study: NCT03523221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Oral
Description: use of one dose of Dexamethasone orally.or placebo in addition to regular treatment of anaphylaxis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone Oral
Description: use of one dose of Dexamethasone orally.or placebo in addition to regular treatment of anaphylaxis
Study: NCT01674244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monitor Only Waitlist
Study: NCT04620161

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pradigastat Tablets 40mg matching Placebo
Description: once daily, oral administration
Study: NCT01112358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analogous GnRH antagonist
Description: Analogous GnRH antagonist will be administered as specified in the arm description.
Study: NCT04620161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pradigastat Tablets 40mg matching Placebo
Description: once daily, oral administration
Study: NCT02297412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02479191

Intervention type: DEVICE
Intervention: Ovation Abdominal Stent Graft Platform

Intervention type: DEVICE
Intervention: Ovation Abdominal Stent Graft Platform
Study: NCT04700150

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tai Chi 2 month
Description: Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breathing, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi 4 month
Description: Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breathing, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
Study: NCT01112358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-hCG
Description: r-hCG will be administered as specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-hCG
Description: r-hCG will be administered as specified in the arm description.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Progesterone will be administered as specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone will be administered as specified in the arm description.
Study: NCT01099137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Vildagliptin 50mg twice a day, orally, for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulphonylurea dose-up
Description: glimepiride dose will be increased by 50% to uncontrolled diabetic patients with glimepiride and metformin
Study: NCT03825757

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl Salicylic Acid
Description: Primaspan 250 mg tablet Acetyl Salicylic Acid
Study: NCT03081689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 360 mg
Description: Nivolumab 360 mg IV Q3W + Followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel 200mg/m2
Description: Paclitaxel 200mg/m2 IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 6
Description: Carboplatin AUC 6 IV Q3W
Study: NCT03594396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300mg bid will be given on days 1-28 days without rest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: A fixed dose of durvalumab 1500 mg is given via IV infusion on Day 15.
Study: NCT03564236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal High Flow Therapy
Description: Nasal High Flow Therapy (nHFT) is an innovative therapy for patients with respiratory diseases. It supplies heated, humidified, and oxygen-enriched air at high flow rates through a nasal cannula. Because the air is provided through an open system with a nasal cannula, it is relatively easy to apply and suggested to be very comfortable for patients. The technique has been shown to be effective in the treatment of hypoxemic respiratory failure, mainly in neonates\[2\] and patients with acute hypoxemic respiratory failure on intensive care units (ICU).\[3\]

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard regular care of a COPD exacerbation
Study: NCT03069716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone Text Messaging
Description: A HIPPA compliant text messaging platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to our mHealth platform via cellular network. Subjects will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule (defined at enrollment). These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.

Intervention type: DEVICE
Group type: OTHER
Intervention: Fitbit Charge HR
Description: The Fitbit Charge HR tri-axial accelerometer will be used to continuously gather data on physical activity, heart rate, and sleep. This device provides feedback in units of activity (steps, stairs climbed, activity time, and exercise time) and heart rate (per second when active, per 5 seconds when inactive). It has been validated against research devices in free-living conditions and is relatively inexpensive.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Charge HR
Description: The Fitbit Charge HR tri-axial accelerometer will be used to continuously gather data on physical activity, heart rate, and sleep. This device provides feedback in units of activity (steps, stairs climbed, activity time, and exercise time) and heart rate (per second when active, per 5 seconds when inactive). It has been validated against research devices in free-living conditions and is relatively inexpensive.
Study: NCT02794571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle or as 1680 mg via IV infusion on Day 1 of each 28-day cycle.
Study: NCT03416725

Intervention type: DEVICE
Intervention: Otoscope
Description: Otoscopic examination will be done to find the presence or absence of perforation, granulation tissue and cholesteatoma.
Study: NCT00000409

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompressive laminectomy
Description: Removal of the hypertrophic inferior and superior articular facets will be performed when they are intruding upon the midline and causing both central and lateral recess stenosis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical treatments
Description: Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated. Any non-operative therapies other than these are accepted and collected as data.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical treatments
Description: Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated. Any non-operative therapies other than these are accepted and collected as data.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fusion--Instrumented
Description: In addition to decompressive laminectomy, additional bilateral non-instrumented or instrumented, i.e., posterior pedicle fixation, posterolateral fusion with autogenous bone grafting (utilizing iliac crest harvested from between the tables and/or local bone) will be performed between the transverse processes and the lateral portion of the superior facets of the involved levels.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fusion-Non-instrumented
Description: additional bilateral non-instrumented or instrumented, i.e., posterior pedicle fixation, posterolateral fusion with autogenous bone grafting (utilizing iliac crest harvested from between the tables and/or local bone) will be performed between the transverse processes and the lateral portion of the superior facets of the involved levels.
Study: NCT00667407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol 1.25 mg
Description: levalbuterol 1.25 mg Period I: administered every 20 minutes for the first 3 doses, and then every 40 minutes for the next 3 doses; then as clinically indicated.~Period II: TID for 3 days (same time of day), then PRN to TID for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racemic Albuterol Sulfate
Description: Racemic Albuterol 2.5 mg Period I: every 20 min for the first 3 doses, then every 40 min for the next 3 doses, then as clinically indicated.~Period II: TID for 3 days then PRN to TID for 7 days
Study: NCT03538548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-RP
Description: CBT-RP is a time-limited, manual guided intervention that aims to develop behavioral and cognitive skills needed to initiate abstinence and prevent relapse. The treatment will help individuals analyze the decision making process to minimize the influence of more immediate reinforcement, develop cognitive strategies to promote the attainment of longer-term goals, practice behavioral strategies to reduce the influence of socially mediated threats to abstinence, and outline explicit plans for managing situations that threaten their goal of abstinence.
Study: NCT02794571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle or as 1680 mg via IV infusion on Day 1 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle or as 1680 mg via IV infusion on Day 1 of each 28-day cycle.